2.1
Tebentafusp (Kimmtrak, Immunocore) is indicated 'as monotherapy for the treatment of human leukocyte antigen (HLA)‑A*02:01-positive adult patients with unresectable or metastatic uveal melanoma'.
2 Information about tebentafusp
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for tebentafusp.
Price
2.3
The list price for tebentafusp (200 micrograms per 1‑ml vial) is £10,114 (BNF online accessed September 2024).
2.4
The company has a commercial arrangement. This makes tebentafusp available to the NHS with a discount. The size of the discount is commercial in confidence.